Bristol Myers Squibb gets Reblozyl EC approval for anemia associated with NTD beta thalassemia

Bristol Myers Squibb (BMY) has secured full marketing authorization for Reblozyl (luspatercept) from the European Commission (EC) for treating anemia associated with non-transfusion-dependent (NTD) beta ... Read More